Rogue Funds, an investment management company, released its fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned 8.59% net of fees in the quarter. This quarter, the Fund’s volatility has increased significantly, and the firm anticipates that it will continue to do so. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024.
In its fourth quarter 2024 investor letter, Rogue Funds emphasized stocks such as Achieve Life Sciences, Inc. (NASDAQ:ACHV). Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a clinical-stage pharmaceutical company. The one-month return of Achieve Life Sciences, Inc. (NASDAQ:ACHV) was 10.68%, and its shares lost 20.83% of their value over the last 52 weeks. On February 14, 2025, Achieve Life Sciences, Inc. (NASDAQ:ACHV) stock closed at $3.42 per share with a market capitalization of $117.613 million.
Rogue Funds stated the following regarding Achieve Life Sciences, Inc. (NASDAQ:ACHV) in its Q4 2024 investor letter:
“Achieve Life Sciences, Inc. (NASDAQ:ACHV) (Stock and Calls): You can read more about this investment on the Rogue Funds blog here. The company released their first trial results in early January and showed zero safety concerns. They have a yearlong trial wrapping up in July (it took 100 individuals from the trial that ended early this month). We should see an NDA in 2Q 2025 and then PDUFA around Q4 2025/Q1 2026 at which point they will probably already be bought out or extremely bid up. There is a very high chance of Priority Review since this drug is already designated as a breakthrough drug. The recent pricing is simply ludicrous and presents an insane IRR. We recently bought more of this company and are astounded at its current price as it does not indicate the current R/R. I believe there will be a decent run-up after this 6 month trial then an incredible run-up if July results come out strong.”
A scientist in a lab coat discussing clinical trial results in a laboratory.
Achieve Life Sciences, Inc. (NASDAQ:ACHV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 6 hedge fund portfolios held Achieve Life Sciences, Inc. (NASDAQ:ACHV) at the end of the third quarter which was 7 in the previous quarter. While we acknowledge the potential of Achieve Life Sciences, Inc. (NASDAQ:ACHV) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article we discussed Achieve Life Sciences, Inc. (NASDAQ:ACHV) and shared Rogue Funds’ views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.